MiR-135a Inhibits Cancer Stem Cell-Driven Medulloblastoma Development by Directly Repressing Arhgef6 Expression

Stem Cells

Volumn 33, Issue 5, 2015, Pages 1377-1389

  Hemmesi, Katayoun ^a   Squadrito, Mario Leonardo ^b   Mestdagh, Pieter ^c   Conti, Valentina ^a   Cominelli, Manuela ^d   Piras, Ignazio S ^e   Sergi, Lucia Sergi ^f   Piccinin, Sara ^g   Maestro, Roberta ^g   Poliani, Pietro L ^d   Speleman, Frank ^c   De Palma, Michele ^b   Galli, Rossella ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c EPFL   (Switzerland)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF BRESCIA   (Italy)

^f Scientific Park of Sardinia Cagliari   (Croatia)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Arhgef6; Cancer stem cell; Medulloblastoma; miR 135a; miRNA signature

Indexed keywords

ARHGEF6 PROTEIN; EYA1 PROTEIN; HAPLN1 PROTEIN; MICRORNA; MICRORNA 135A; PROTEIN; PROTEIN P53; PROTEIN PATCHED; TRANSCRIPTION FACTOR HOXA10; UNCLASSIFIED DRUG; ARHGEF6 PROTEIN, MOUSE; MIRN135 MICRORNA, MOUSE; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL FRACTIONATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE REPRESSION; GENE TARGETING; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; MISSENSE MUTATION; MOUSE; NEURAL STEM CELL; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL AGGREGATION; CELL TRANSFORMATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CELL AGGREGATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; GENE EXPRESSION PROFILING; MEDULLOBLASTOMA; MICE, INBRED C57BL; MICRORNAS; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928579497     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1958     Document Type: Article

References (51)

1. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: The end of the beginning. Nat Rev Cancer 2012; 12: 818-834.
2. Hatten ME, Roussel MF., Development and cancer of the cerebellum. Trends Neurosci 2011; 34: 134-142.
3. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468: 1095-1099.
4. Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009; 15: 135-147.
5. Ward RJ, Lee L, Graham K, et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res 2009; 69: 4682-4690.
6. Corno D, Pala M, Cominelli M, et al. Gene signatures associated with mouse postnatal hindbrain neural stem cells and medulloblastoma cancer stem cells identify novel molecular mediators and predict human medulloblastoma molecular classification. Cancer Discov 2012; 2: 554-568.
7. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24: 1924-1931.
8. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008; 3: e3088.
9. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2010; 29: 1400-1407.
10. Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: An integrated clinical and molecular analysis. Lancet Oncol 2013; 14: 1200-1207.
11. Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277: 1109-1113.
12. Schuller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008; 14: 123-134.
13. Kawauchi D, Robinson G, Uziel T, et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012; 21: 168-180.
14. Pei Y, Moore CE, Wang J, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012; 21: 155-167.
15. Pöschl J, Stark S, Neumann P, et al. Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. Acta Neuropathol 2014; 128: 123-136.
16. Vanner RJ, Remke M, Gallo M, et al. Quiescent Sox2 cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell 2014; 26: 33-47.
17. Kent OA, Mendell JT., A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 2006; 25: 6188-6196.
18. Kasinski AL, Slack FJ., Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-864.
19. Ferretti E, De Smaele E, Po A, et al. MicroRNA profiling in human medulloblastoma. Int J Cancer 2009; 124: 568-577.
20. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2010; 29: 1424-1430.
21. Lv SQ, Kim YH, Giulio F, et al. Genetic alterations in microRNAs in medulloblastomas. Brain Pathol 2012; 22: 230-239.
22. Mestdagh P, Feys T, Bernard N, et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008; 36: e143.
23. Amendola M, Passerini L, Pucci F, et al. Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther 2009; 17: 1039-1052.
24. Tang WJY, Mu X, Xu L, et al. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal 2014; 26: 1420-1426.
25. Squadrito ML, Pucci F, Magri L, et al. miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep 2012; 1: 141-154.
26. Freed-Pastor WA, Prives C., Mutant p53: One name, many proteins. Genes Dev 2012; 26: 1268-1286.
27. Whibley C, Odell AF, Nedelko T, et al. Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol Chem 2010; 285: 11326-11335.
28. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-48.
29. Genovesi LA, Carter KW, Gottardo NG, et al. Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. PLoS One 2011; 6: e23935.
30. Bai AH, Milde T, Remke M, et al. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol 2012; 123: 529-538.
31. Silber J, Hashizume R, Felix T, et al. Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol 2013; 15: 83-90.
32. Murphy BL, Obad S, Bihannic L, et al. Silencing of the miR-17∼92 cluster family inhibits medulloblastoma progression. Cancer Res 2013; 73: 7068-7078.
33. Fiaschetti G, Abela L, Nonoguchi N, et al. Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma. Br J Cancer 2014; 110: 636-647.
34. Xu Q, Pan Y, Li L, et al. MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1. Brain Pathol 2014; 24: 568-583.
35. Liu C, Tang DG., MicroRNA regulation of cancer stem cells. Cancer Res 2011; 71: 5950-5954.
36. Sun X, Jiao X, Pestell TG, et al. MicroRNAs and cancer stem cells: The sword and the shield. Oncogene 2014; 33: 4967-4977.
37. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
38. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
39. Chen Y, Zhang J, Wang H, et al. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer 2012; 12: 111.
40. Díaz-Beyá M, Brunet S, Nomdedéu J, et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia 2014; 28: 804-812.
41. Munari E, Marchionni L, Chitre A, et al. Clear cell papillary renal cell carcinoma: Micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol 2014; 45: 1130-1138.
42. Hidaka H, Seki N, Yoshino H, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012; 3: 44-57.
43. Tang W, Jiang Y, Mu X, et al. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal 2014; 26: 1420-1426.
44. Wu H, Huang M, Cao P, et al. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther 2012; 13: 281-288.
45. Wu S, Lin Y, Xu D, et al. MiR-135a functions as a selective killer of malignant glioma. Oncogene 2012; 31: 3866-3874.
46. Rosenberger G, Gal A, Kutsche K., AlphaPIX associates with calpain 4, the small subunit of calpain, and has a dual role in integrin-mediated cell spreading. J Biol Chem 2005; 280: 6879-6889.
47. Rosenberger G, Kutsche K., AlphaPIX and betaPIX and their role in focal adhesion formation. Eur J Cell Biol 2006; 85: 265-274.
48. Zhang H, Webb DJ, Asmussen H, et al. A GIT1/PIX/Rac/PAK signaling module regulates spine morphogenesis and synapse formation through MLC. J Neurosci 2005; 25: 3379-3388.
49. Totaro A, Tavano S, Filosa G, et al. Biochemical and functional characterisation of alphaPIX, a specific regulator of axonal and dendritic branching in hippocampal neurons. Biol Cell 2012; 104: 533-552.
50. Yokota T, Kouno J, Adachi K, et al. Identification of histological markers for malignant glioma by genome-wide expression analysis: Dynein, alpha-PIX and sorcin. Acta Neuropathol 2006; 111: 29-38.
51. Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013; 31: 2927-2935.